mondobiotech holding AG (SIX:RARE) announces the exercise of the convertion rights by BioPharma Invest AG

January 25, 2013 Stans, Switzerland

mondoBIOTECH holding AG (“mondoBIOTECH”), a Swiss–based drug discovery company focused on repurposing drugs in rare and neglected diseases and listed on the SIX Swiss Exchange (SIX: RARE), today announces that BioPharma Invest AG (BPI) has exercised its right to convert the CHF 2.5 million loan facility granted to the Company on 11th November 2011 into common shares of the Company.

The loan is to be converted into common shares at the average stock market price of the last 60 days prior to today’s notice of conversion. The respective shares will have to be issued by the Company by way of a dedicated share capital increase.

About mondoBIOTECH mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its internally developed Search&Match methodology. In Search&Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners. For further information please contact mondoBIOTECH holding AG Andreas Hildenbrand, Lemongrass Communications Tel.: +41 44 202 5268 andreas.hildenbrand@lemongrass-communications.com Disclaimer This communication expressly or implicitly contains certain forward-looking statements concerning mondoBIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondoBIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondoBIOTECH holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.